Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $117.00 Price Target at TD Cowen

27 Feb 2026, 11:20 by Sarita Garza · The Markets Daily

Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its target price lifted by TD Cowen from $115.00 to $117.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

MIRM has been the subject of several other research reports. Leerink Partners decreased their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday. Citizens Jmp decreased their target price on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Morgan Stanley boosted their price target on shares of Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Royal Bank Of Canada decreased their price objective on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $114.92.

Check Out Our Latest Stock Report on Mirum Pharmaceuticals

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $92.19 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $109.28. The firm has a market cap of $4.74 billion, a PE ratio of -192.06 and a beta of 0.49. The firm’s fifty day moving average is $93.11 and its 200-day moving average is $78.90.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.98%. The business’s revenue for the quarter was up 49.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.00 earnings per share. Sell-side analysts predict that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,631 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the sale, the chief operating officer directly owned 20,655 shares in the company, valued at approximately $2,133,661.50. This trade represents a 11.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer owned 43,741 shares in the company, valued at $4,207,446.79. This represents a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 45,136 shares of company stock worth $4,352,029. Corporate insiders own 14.36% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Emerald Advisers LLC lifted its stake in Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock valued at $27,095,000 after acquiring an additional 63,834 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $808,000. Candriam S.C.A. raised its holdings in shares of Mirum Pharmaceuticals by 8.0% in the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock valued at $29,546,000 after purchasing an additional 30,021 shares during the last quarter. TimesSquare Capital Management LLC bought a new position in shares of Mirum Pharmaceuticals during the third quarter valued at about $22,041,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in Mirum Pharmaceuticals during the third quarter worth about $503,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Revenue beat and strong product growth—Mirum posted ~50% y/y revenue growth driven by Livmarli and other bile-acid therapies, beating Street revenue estimates, which supports the company’s top-line trajectory. Article Title
Positive Sentiment: Corporate release and call provide detail and FY revenue guide—Mirum’s press release and earnings call outlined operations and gave FY2026 revenue guidance ($630M–$650M), offering a revenue roadmap for investors even as EPS guidance/detail was limited. Article Title
Positive Sentiment: Analysts largely remain bullish — multiple firms raised or reiterated positive ratings and targets (TD Cowen, Stifel Nicolaus, RBC and others continue to show upside vs. the current price), signaling analyst confidence in longer-term upside despite short-term noise. Article Title
Neutral Sentiment: Transcripts and analysis available—Earnings-call transcripts and analyst writeups (Seeking Alpha, The Motley Fool, Zacks) give more color for investors deciding whether the EPS miss is a one-off or structural. Use these to dig into margins, SG&A, and commercial execution details. Article Title Article Title
Negative Sentiment: EPS miss and margin concerns—Mirum reported ($0.11) EPS vs. a ~$0.02 consensus, a significant miss that triggered the selloff despite the revenue beat; investors are focused on margins, profitability timeline, and whether EPS guidance will be conservative. Article Title
Negative Sentiment: Immediate market reaction and volume—Coverage and commentary (AAII and others) point to the EPS miss + any perceived conservative guidance as the proximate cause of today’s decline; heavy volume suggests short-term technical selling even as analysts debate the longer-term story. Article Title

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.